Glutathione and Glutaredoxin Act as a Backup of Human Thioredoxin Reductase 1 to Reduce Thioredoxin 1 Preventing Cell Death by Aurothioglucose

被引:189
作者
Du, Yatao [1 ]
Zhang, Huihui [1 ]
Lu, Jun [1 ]
Holmgren, Arne [1 ]
机构
[1] Karolinska Inst, Dept Med Biochem & Biophys, Div Biochem, S-17177 Stockholm, Sweden
基金
瑞典研究理事会;
关键词
MAMMALIAN THIOREDOXIN; CANCER-THERAPY; IN-VIVO; PROTEIN OXIDATION; DNA-REPLICATION; REDOX STATE; SYSTEM; EBSELEN; DITHIOTHREITOL; IDENTIFICATION;
D O I
10.1074/jbc.M112.392225
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Thioredoxin reductase 1 (TrxR1) in cytosol is the only known reductant of oxidized thioredoxin 1 (Trx1) in vivo so far. We and others found that aurothioglucose (ATG), a well known active-site inhibitor of TrxR1, inhibited TrxR1 activity in HeLa cell cytosol but had no effect on the viability of the cells. Using a redox Western blot analysis, no change was observed in redox state of Trx1, which was mainly fully reduced with five sulfhydryl groups. In contrast, auranofin killed cells and oxidized Trx1, also targeting mitochondrial TrxR2 and Trx2. Combining ATG with ebselen gave a strong synergistic effect, leading to Trx1 oxidation, reactive oxygen species accumulation, and cell death. We hypothesized that there should exist a backup system to reduce Trx1 when only TrxR1 activity was lost. Our results showed that physiological concentrations of glutathione, NADPH, and glutathione reductase reduced Trx1 in vitro and that the reaction was strongly stimulated by glutaredoxin1. Simultaneous depletion of TrxR activity by ATG and glutathione by buthionine sulfoximine led to overoxidation of Trx1 and loss of HeLa cell viability. In conclusion, the glutaredoxin system and glutathione have a backup role to keep Trx1 reduced in cells with loss of TrxR1 activity. Monitoring the redox state of Trx1 shows that cell death occurs when Trx1 is oxidized, followed by general protein oxidation catalyzed by the disulfide form of thioredoxin.
引用
收藏
页码:38210 / 38219
页数:10
相关论文
共 55 条
  • [1] Ahsan MK, 2009, ANTIOXID REDOX SIGN, V11, P2741, DOI [10.1089/ars.2009.2683, 10.1089/ARS.2009.2683]
  • [2] The thioredoxin system in cancer
    Arner, Elias S. J.
    Holmgren, Arne
    [J]. SEMINARS IN CANCER BIOLOGY, 2006, 16 (06) : 420 - 426
  • [3] Azad MB, 2009, ANTIOXID REDOX SIGN, V11, P777, DOI 10.1089/ARS.2008.2270
  • [4] Thioredoxin reductase as a pathophysiological factor and drug target
    Becker, K
    Gromer, S
    Schirmer, RH
    Müller, S
    [J]. EUROPEAN JOURNAL OF BIOCHEMISTRY, 2000, 267 (20): : 6118 - 6125
  • [5] Redox imbalance
    Berg, D
    Youdim, M
    Riederer, P
    [J]. CELL AND TISSUE RESEARCH, 2004, 318 (01) : 201 - 213
  • [6] Bersani NA, 2002, METHOD ENZYMOL, V347, P317
  • [7] Thioredoxin reductase: A target for gold compounds acting as potential anticancer drugs
    Bindoli, Alberto
    Rigobello, Maria Pia
    Scutari, Guido
    Gabbiani, Chiara
    Casini, Angela
    Messori, Luigi
    [J]. COORDINATION CHEMISTRY REVIEWS, 2009, 253 (11-12) : 1692 - 1707
  • [8] Structural and functional changes in proteins induced by free radical-mediated oxidative stress and protective action of the antioxidants N-tert-butyl-α-phenylnitrone and vitamin E
    Butterfield, DA
    Koppal, T
    Howard, B
    Subramaniam, R
    Hall, N
    Hensley, K
    Yatin, S
    Allen, K
    Aksenov, M
    Aksenov, M
    Carney, J
    [J]. TOWARDS PROLONGATION OF THE HEALTHY LIFE SPAN: PRACTICAL APPROACHES TO INTERVENTION, 1998, 854 : 448 - 462
  • [9] Respiration-dependent H2O2 Removal in Brain Mitochondria via the Thioredoxin/Peroxiredoxin System
    Drechsel, Derek A.
    Patel, Manisha
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2010, 285 (36) : 27850 - 27858
  • [10] Eruslanov E, 2010, METHODS MOL BIOL, V594, P57, DOI 10.1007/978-1-60761-411-1_4